7 Rue des Chasseurs Ardennais
4041 ANGLEUR
Belgium
[email protected] osivax.com

Follow them

Osivax is a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses.

About

Osivax is a clinical-stage biotech company leveraging platform technology, oligoDOM™, to transform the respiratory virus vaccine landscape with pan-flu and pan-covid-19 vaccines delivered in one single shot. The company is establishing proof of concept with its broad-spectrum “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trial with over 1,200 participants and encouraging Proof of Concept efficacy in human.

Related news

News

Learn more

Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836

    Press release

14.11.2024

Learn more

Osivax and KM Biologics Enter Exclusive License Option Agreement for Broad-Spectrum “Universal” Influenza Vaccine in Japan

    Press release

10.09.2024

Learn more

Osivax Completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033

    Press release

25.06.2024

Related jobs

Jobs

Learn more

Project Management Office (PMO) Manager

Lyon | Permanent contract - Full time | Project management